Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis
- PMID: 21396468
- PMCID: PMC3568396
- DOI: 10.1016/j.joca.2010.08.019
Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis
Abstract
Objective: Osteoarthritis (OA) is a chronic and slowly progressive disease for which biomarkers may be able to provide a more rapid indication of therapeutic responses to therapy than is currently available; this could accelerate and facilitate OA drug discovery and development programs. The goal of this document is to provide a summary and guide to the application of in vitro (biochemical and other soluble) biomarkers in the development of drugs for OA and to outline and stimulate a research agenda that will further this goal.
Methods: The Biomarkers Working Group representing experts in the field of OA biomarker research from both academia and industry developed this consensus document between 2007 and 2009 at the behest of the Osteoarthritis Research Society International Federal Drug Administration initiative (OARSI FDA initiative).
Results: This document summarizes definitions and classification systems for biomarkers, the current outcome measures used in OA clinical trials, applications and potential utility of biomarkers for development of OA therapeutics, the current state of qualification of OA-related biomarkers, pathways for biomarker qualification, critical needs to advance the use of biomarkers for drug development, recommendations regarding practices and clinical trials, and a research agenda to advance the science of OA-related biomarkers.
Conclusions: Although many OA-related biomarkers are currently available they exist in various states of qualification and validation. The biomarkers that are likely to have the earliest beneficial impact on clinical trials fall into two general categories, those that will allow targeting of subjects most likely to either respond and/or progress (prognostic value) within a reasonable and manageable time frame for a clinical study (for instance within 1-2 years for an OA trial), and those that provide early feedback for preclinical decision-making and for trial organizers that a drug is having the desired biochemical effect. As in vitro biomarkers are increasingly investigated in the context of specific drug treatments, advances in the field can be expected that will lead to rapid expansion of the list of available biomarkers with increasing understanding of the molecular processes that they represent.
Copyright © 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
While individuals from pharmaceutical, biotechnology and device companies actively participated in on-going working group discussions, due to the conflict of interest policy enacted by OARSI, these individuals were not allowed to vote on the final recommendations made by OARSI to the Food and Drug Administration.
Figures
Similar articles
-
OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Osteoarthritis Cartilage. 2015 May;23(5):686-97. doi: 10.1016/j.joca.2015.03.002. Osteoarthritis Cartilage. 2015. PMID: 25952342 Free PMC article. Review.
-
Clinical monitoring in osteoarthritis: Biomarkers.Osteoarthritis Cartilage. 2022 Sep;30(9):1159-1173. doi: 10.1016/j.joca.2021.04.019. Epub 2021 Sep 16. Osteoarthritis Cartilage. 2022. PMID: 34536529 Free PMC article.
-
OARSI-FDA initiative: defining the disease state of osteoarthritis.Osteoarthritis Cartilage. 2011 May;19(5):478-82. doi: 10.1016/j.joca.2010.09.013. Epub 2011 Mar 23. Osteoarthritis Cartilage. 2011. PMID: 21396464
-
Imaging biomarker validation and qualification report: sixth OARSI Workshop on Imaging in Osteoarthritis combined with third OA Biomarkers Workshop.Osteoarthritis Cartilage. 2013 Jul;21(7):939-42. doi: 10.1016/j.joca.2013.04.014. Epub 2013 Apr 30. Osteoarthritis Cartilage. 2013. PMID: 23639411 Free PMC article.
-
Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine.Biomarkers. 2015;20(8):540-6. doi: 10.3109/1354750X.2015.1123363. Biomarkers. 2015. PMID: 26954785 Free PMC article. Review.
Cited by
-
A Single Bout of High Heels Dancing Causes an Increase in Circulating Markers of Muscle Tissue Degradation and MMP-3 in Young Healthy Women.Transl Sports Med. 2023 Jun 1;2023:8852889. doi: 10.1155/2023/8852889. eCollection 2023. Transl Sports Med. 2023. PMID: 38654916 Free PMC article.
-
Infrared Spectroscopy of Synovial Fluid Shows Accuracy as an Early Biomarker in an Equine Model of Traumatic Osteoarthritis.Animals (Basel). 2024 Mar 22;14(7):986. doi: 10.3390/ani14070986. Animals (Basel). 2024. PMID: 38612225 Free PMC article.
-
Impact of diabetes mellitus on osteoarthritis: a scoping review on biomarkers.Expert Rev Mol Med. 2024 Apr 12;26:e8. doi: 10.1017/erm.2024.7. Expert Rev Mol Med. 2024. PMID: 38606593 Free PMC article. Review.
-
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis.Nat Rev Rheumatol. 2024 May;20(5):272-289. doi: 10.1038/s41584-024-01102-y. Epub 2024 Apr 11. Nat Rev Rheumatol. 2024. PMID: 38605249 Review.
-
Sugar-coated bullets: Unveiling the enigmatic mystery 'sweet arsenal' in osteoarthritis.Heliyon. 2024 Mar 11;10(6):e27624. doi: 10.1016/j.heliyon.2024.e27624. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38496870 Free PMC article. Review.
References
-
- Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007;81:104–107. - PubMed
-
- Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. - PubMed
-
- FDA FaDA. Guidance for Industry: E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. 2008.
-
- Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006;14:723–727. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials